We’ve seen a massive expansion in mRNA technologies. We’re now struggling to keep up with training workforces to manufacture these products so there is a need – an acute need – for CPI’s RNA Training Academy.

The COVID-19 pandemic highlighted the opportunities that RNA therapeutics can offer. CPI’s RNA Training Academy will upskill existing GMP operators to prepare them for manufacturing RNA for the UK market, and beyond, to ensure that the UK has the required biomanufacturing capacity to meet future demand.

CPI is very well placed to provide this training. Its experts have a broad range of technical experience through their work on a number of RNA projects, using a variety of approaches. This Training Academy will therefore expose people to a wide variety of ways of making RNA that can be adapted and used with many skillsets and facilities.

CPI bridges the gap between industry and academia. Through the RNA Training Academy, CPI is bringing its industry expertise and collaborations to train the next generation of RNA specialists. This is critically important to making the UK a hotspot for RNA technologies.